4Q Revenues: $3.8 billion (flat)
4Q Earnings: $961 million (+15%)
FY Revenues: $15.0 billion (+2%)
FY Earnings: $4.2 billion (+33%)
Comments: Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million. Foreign exchange negatively impacted sales by $30 million. Aranesp sales were down 15% to $706 million in the quarter and down 14% to $3.1 billion for the year due to a decline in demand and additional product label changes. Sales of Epogen were $646 million (+1%) and for the year sales were down 1% to $2.5 billion. Combined sales of Neulasta and Neupogen increased 6% to $1.2 billion in the quarter and 9% to $4.7 billion for the year. Sales of Enbrel increased 7% in the quarter to $913 million and 13% to 3.6 billion for the year. R&D expenses were down 2% to $770 million in the quarter.